A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
A Randomised, Placebo-controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0487-0111 in Participants With Overweight or Obesity
Sponsor: Novo Nordisk A/S
A PHASE2 clinical study on Obesity and Overweight, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 8 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
Phase: PHASE1 → PHASE2
▶ Show 3 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Jan 2024 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE1
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .